$CNTG News

Last published 2y ago

2y agoCNTG CNTGFCENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet NeurologyGlobeNewswireRostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over subcohort of 3,350
2y agoCNTGCENTOGENE Receives Delisting Notice From NasdaqGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced
2y agoCNTGCENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic FactorsGlobeNewswireInitial data from largest international Parkinson's disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential
2y agoCNTGC-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug DevelopmentGlobeNewswireTUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene
2y agoCNTGCENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General MeetingGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
2y agoCNTGCENTOGENE Reports Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswireReported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the
2y agoCNTGCENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
2y agoCNTGCENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
2y agoCNTGCENTOGENE Receives Nasdaq Non-Compliance NoticeGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("Centogene", "we", or the "Company"), the essential life science partner for data-driven answers in
2y agoCNTG TAKCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersGlobeNewswireLongstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) --
2y agoCNTGCENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
2y agoCNTGCENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
2y agoCNTGCENTOGENE Explores Strategic AlternativesGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
2y agoCNTGCENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
2y agoCNTGCENTOGENE Receives French Research Tax Credit AccreditationGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
2y agoCNTGCENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using MultiomicsGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and
2y agoCNTGCENTOGENE Announces Preliminary Full Year 2023 RevenueGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
2y agoCNTGCENTOGENE Announces Voting Results of Extraordinary General MeetingGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
2y agoCNTGCENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
2y agoCNTGCENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionGlobeNewswireLifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research
2y agoCNTGCENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and ParkinsonismGlobeNewswireCollaborative research initiative leveraged CENTOGENE's Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected
3y agoCNTGCENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic OfferingGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
3y agoCNTGCENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
3y agoCNTGCENTOGENE Reports First Half 2023 Financial ResultsGlobeNewswireFirst half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10%
3y agoCNTGCENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease PatientsGlobeNewswireResults from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of patients and improve
3y agoCNTGCENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life science partner for data-driven answers in rare and
3y agoCNTGCENTOGENE to Participate in Upcoming Conferences in AugustGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
3y agoCNTGCENTOGENE Regains Compliance With Nasdaq Listing RequirementsGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
3y agoCNTGCENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease CohortGlobeNewswireInclusion of 602 patients from 47 countries represents the world's largest and most heterogeneous Niemann-Pick type C1 disease (NPC1) cohortStudy identified 287 unique Pathogenic/Likely Pathogenic (P/LP) variants, 73 of
3y agoCNTGCENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General MeetingGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative
3y agoCNTGCENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million InvestmentGlobeNewswireJoint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) based in RiyadhJV focuses on
3y agoCNTGCENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life science partner for data-driven answers in rare and
3y agoCNTGCENTOGENE Reports Full Year 2022 Financial ResultsGlobeNewswireFull Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant
3y agoCNTGCENTOGENE to Participate in Upcoming Conferences in MayGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
3y agoCNTGCENTOGENE Receives Nasdaq Non-Compliance NoticeGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("Centogene", "we", or the "Company"), the essential life science partner for data-driven answers in
3y agoCNTGCENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics PipelineGlobeNewswireEnabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World CENTOGENE's FilterTool aims to fuel rapid, reliable analysis for diagnosis and research of rare genetic diseases by
3y agoCNTGCENTOGENE to Participate in Upcoming Conferences in AprilGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
3y agoCNTGCENTOGENE Launches NEW CentoGenome®, World's Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative DiseasesGlobeNewswireAims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosisCombines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with the CENTOGENE
3y agoCNTG TAKCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersGlobeNewswireThe global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis plays a critical role in
3y agoCNTGCENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - PharmaGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
3y agoCNTGCENTOGENE to Participate in Upcoming Conferences in MarchGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 08, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
3y agoCNTGIn the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)GlobeNewswireFTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) geneThe observational EFRONT study is increasing the number of sites to
3y agoCNTGCENTOGENE Regains Compliance With Nasdaq Listing RequirementsGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
3y agoCNTGCENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease DayGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
3y agoCNTG TWSTTwist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support DiagnosticsBusiness WireCombining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary cancer around the world Twist Bioscience Corporation (NASDAQ:TWST), a
3y agoCNTGCENTOGENE and Denali Therapeutics Extend World's Largest Observational Study on Parkinson's Disease GeneticsGlobeNewswireThe Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for patientsHaving recently
3y agoCNTGPremier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical DevelopmentPR NewswireLeveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MORRISVILLE, N.C., and CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, Jan. 9, 2023
3y agoCNTGCENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San FranciscoGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today
3y agoCNTGCENTOGENE Reports Second Quarter and First Half 2022 Financial ResultsGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,
3y agoCNTGCENTOGENE Receives Nasdaq Non-Compliance NoticeGlobeNewswireCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, has